EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?

Fausto Petrelli iD, Antonio Ghidini iD, Italo Sarno, Alessandro Iaculli, Angeli Irene, Giovanna Moleri, Mauro Rossitto, Lorenzo Dottorini

Tumori Journal · 2025

DOI: 10.1177/03008916251328539 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Tumori Journal, 2025. Verfasst von Fausto Petrelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: The strategic addition of immune checkpoint inhibitors (ICIs) to chemotherapy (CT) offers a potential paradigm shift in the treatment of elderly cancer patients. This systematic review evaluates the impact of ICIs combined with CT on the overall survival (OS) of patients aged 65 and older. Material and methods: Using the terms "immune checkpoint inhibitors" and (PD-1 or PD-L1 or CTLA-4) and ("cancer" or "carcinoma") and ("elderly" or "older" or "65 years" or "70 years"), we searched PubMed, Embase, and the Cochrane Library through March 2024. We selected only English language, phase II-III randomized controlled trials comparing first-line CT + ICIs vs. CT alone for metastatic cancers, with subgroups reporting outcomes of elderly patients (according to the authors’ cutoff of at least 65 years). Hazard ratios (HR) for OS with relative 95% confidence intervals (95%CI) were extracted from each study. Summary HR was calculated using random- or fixed-effects models, depending on the heterogeneity of the included studies Results: The study synthesizes data from 46 phase III randomized controlled trials, focusing on first-line treatments for metastatic cancers, where ICIs plus CT are compared against CT. The meta-analysis reveals that the combination therapy significantly improves OS in certain cancer types like lung cancers (HR=0.79, 95%CI 0.73-0.86; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansAgedRandomized Controlled Trials as TopicAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

chemotherapyelderly cancer patientsimmune checkpoint inhibitorsmeta-analysisoverall survival

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy.
  • Oncology Unit, Casa di Cura Igea, Milano, Italy.
  • Oncology Unit, CROB, Rionero in Vulture, Italy.
  • Oncology Unit, ASST Bergamo Est, Seriate, Italy.
  • Public relations office, Direzione Generale, ASST Bergamo Ovest, Treviglio Italy.

ORCID-Profile: Fausto Petrelli, Antonio Ghidini

Zitieren

APA

Petrelli, F., Ghidini, A., Sarno, I., Iaculli, A., Irene, A., Moleri, G., Rossitto, M., & Dottorini, L. (2025). Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?. Tumori Journal. https://doi.org/10.1177/03008916251328539

Vancouver

Petrelli F, Ghidini A, Sarno I, Iaculli A, Irene A, Moleri G, et al. Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?. Tumori Journal. 2025. doi:10.1177/03008916251328539

BibTeX
@article{Petrelli2025,
  author = {Petrelli, Fausto and Ghidini, Antonio and Sarno, Italo and Iaculli, Alessandro and Irene, Angeli and Moleri, Giovanna and Rossitto, Mauro and Dottorini, Lorenzo},
  title = {Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?},
  journal = {Tumori Journal},
  year = {2025},
  doi = {10.1177/03008916251328539}
}
Kostenlos starten →